Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
FORMULATION DEVELOPMENT TECHNOLOGY - A Novel Drug Delivery System That Offers Zero-Order/Near Zero-Order Release Profile of Low-Dosage Strength Tablets Containing Highly Soluble Actives October 5, 2015
Thomas B. Gold, PhD, was awarded a US patent; the intellectual property centers on formulation development technology that allows for the steady, continuous release of API over a particular duration of time to mitigate variations or spikes in therapeutic benefit.
FORMULATION FORUM - Manufacturing of Solid Oral Dosage Forms by Direct Compression June 3, 2025
Jim Huang, PhD, and Shaukat Ali, PhD, say not all excipients are well suited for DC, so challenges remain to find excipients compatible to DC due to certain physicochemical properties associated with poor flowability, lack of plasticity, flexibility, and compressibility.
EXECUTIVE INTERVIEW - PCI Pharma Services: Driving Precision, Agility & Partnership in Complex Drug Development May 7, 2025
Anshul Gupte, PhD, RAC Drugs, VP of Pharmaceutical Development at PCI Pharma Services, talks about phase-appropriate development, technical hurdles in pharmaceutical sciences, building agile teams, and what sponsors should prioritize when planning their strategy for novel therapies.
NASAL DRUG DELIVERY - Overcoming the Challenges of Formulation Development May 7, 2025
Eric Kaneps explores the nasal drug delivery landscape, including the benefits of nasal administration compared with other routes and the unique formulation challenges associated with this delivery method.
SPECIAL FEATURE - Bioavailability & Solubility: The Promise of Novel Ingredients April 4, 2025
Contributor Cindy H. Dubin, speaks with several innovating companies to discuss the use of novel excipients as well as other methods and technologies for tackling bioavailability and solubility once and for all.
FORMULATION FORUM - Lymphatic versus Portal Drug Delivery: An Understanding of Drug Oral Absorption & Food Effect April 3, 2025
Jim Huang, PhD, and Shaukat Ali, PhD, say the lymphatic system is a distinctive route that is essential for drug transport and delivery of large and lipophilic molecules by alleviating the challenges in penetrating blood capillaries.
Acumen Pharmaceuticals Announces Topline Results From Phase 1 Study of Subcutaneous Formulation of Sabirnetug March 19, 2025
Acumen Pharmaceuticals, Inc. recently announced topline results from its Phase 1 study comparing pharmacokinetics (PK) between subcutaneous (SC) and intravenous (IV)...Tiziana Life Sciences Announces Agreement for Product Development Services With Renaissance Lakewood February 21, 2025
Tiziana Life Sciences, Ltd. recently announced a product development services agreement with Renaissance Lakewood LLC, a leading Contract Development and...LEADERSHIP PANEL - What Will Have the Most Impact on Drug Development in 2025? February 11, 2025
Contributor Cindy H. Dubin asked several life science leaders what they believe will have the greatest impact on drug development in 2025.
FORMULATION FORUM - Nanoparticle Technologies for Oral Delivery of Peptides & Proteins February 11, 2025
Jim Huang, PhD, and Shaukat Ali, PhD, examine various nanoparticle technologies in oral delivery of large molecules.
VACCINE DEVELOPMENT - Enhancing Pandemic Preparedness With Mosaic-8b Nanoparticles February 10, 2025
Leonardo Magneschi, PhD, says although the mosaic-8b vaccine is still in early development, it has the potential to enable a broad and cross-reactive immunization strategy that could provide comprehensive protection against known and unknown sarbecoviruses.
OUTSOURCING PHARMA DEVELOPMENT - Harnessing CDMOs for Innovation & Efficiency February 10, 2025
Rohtash Kumar, PhD, says a strategic partnership with a trusted CDMO can provide many benefits ranging from experts’ insights to state-of-the-art equipment. However, there are several considerations that developers should evaluate prior to engaging with a CDMO to maximize their partnership.
Iconovo & Lonza to Collaborate on the Formulation Development of an Intranasal Biologic January 14, 2025
Iconovo AB, a leader in the development of inhalable drugs based on proprietary inhalers and dry powder formulations, today announced...Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model December 18, 2024
Channel Therapeutics Corporation recently announced it achieved its endpoints in two pre-clinical in vivo models of its nerve block formulations...FORMULATION FORUM - Nanoparticle Technology for Nose-to-Brain Drug Delivery December 10, 2024
Jim Huang, PhD, and Shaukat Ali, PhD, say as we continue our investigation of innovative delivery routes for drug molecules besides the parenteral and oral routes, the IN route remains the future method for drug delivery to the brain.
Impact BioMedical Inc. Announces Issuance of Patent for Linebacker Technology Targeting Inflammatory Disease October 15, 2024
Impact BioMedical Inc. recently announced a significant milestone in its innovative Linebacker technology platform. The Canadian Intellectual Property Office has...Hovione & Zerion Pharma Create Joint Venture to Further Expand Use of Dispersome Technology October 3, 2024
Hovione Farmaciência, S.A. and Zerion Pharma A/S recently announced they have expanded their partnership to accelerate the development of the...DRUG DELIVERY - Advancements in Transdermal Delivery Systems: A Focus on Invisicare® Technology for Obesity Treatment October 2, 2024
James A. Roszell, PhD, and Doreen McMorran demonstrate how this technology has demonstrated potential in the transdermal administration of glucagon-like peptide-1 (GLP-1) agonists and cannabinoid receptor type 1 (CB-1) antagonists, primarily targeting obesity management and other conditions requiring glucose regulation.
FORMULATION DEVELOPMENT - Practical & Purposeful: Creating Novel Compounds Via Rediscovery R&D & Cannabinoid Molecules October 1, 2024
Mark Bleackley, PhD, says as time goes on, more companies will discover the benefits of drug repurposing – and how to successfully use such strategies to develop new, patentable drug products. In fact, repurposing could be exactly what’s needed to enable pharmaceutical and biotechnology companies to more swiftly develop treatments for indications with significant unmet medical needs.
PRECLINICAL/CLINICAL STUDIES - Preclinical Toxicology vs Clinical: Key Considerations in Using Lipid-Based Formulations October 1, 2024
Anette Müllertz, PhD, Grace Furman, PhD, and Lisa Caralli say developers should first understand the developability challenges for their molecule, then a toolkit of enabling technologies can be identified to overcome those factors and individually leveraged to create fit for purpose formulations for use in preclinical and clinical studies.
Company Profiles
Lyophilization Technology, Inc.
Lyophilization Technology, Inc. 30 Indian Drive Ivyland, PA 18974-1431 T: (215) 396-8373 F: (215) 396-8375 E: inquiry@lyo-t.com W: www.lyotechnology.com WHO...DRUG-DEVICE DEVELOPMENT - Exploring the Complexities of Drug-Device Combination Products
Jeremy Guo, Senior Vice President at WuXi Biologics, and colleagues explain that many factors need to be taken into account when producing a Drug-Device Combination Product from development testing to fill/finish and assembly.
